Acusphere AI-700 Imaging Agent Phase III Protocols Expected By Early 2002
Executive Summary
Acusphere plans to submit Phase III protocols for its ultrasound contrast agent AI-700 to FDA by early 2002.
You may also be interested in...
DuPont Pictures Definity Imaging Agent Launch Supported By User Training
DuPont Pharmaceuticals will support an autumn launch of its Definity echocardiography ultrasound contrast agent with a user training program.
Ivax Starts Shipping Generic Paclitaxel; Oral Formulation Paxoral In Phase II
Ivax has started shipping its generic version of Bristol's injectable anti-tumor agent Taxol (paclitaxel), Ivax President Neil Flanzraich told the CIBC World Markets Healthcare Conference in New York City Oct. 25.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011